Just as US pharma giant Pfizer (NYSE: PFE) says it is pulling out of the Alzheimer’s and Parkinson’s disease discovery space, and Axovant Sciences (Nasdaq: AXON) reported a serious setback in its dementia program, a new Franco-American research partnership has been announced in this difficult sector, which has seen a number of other high-profile failures.
French pharma firm Servier and USA-headquartered biotech Treventis, both privately-owned, announced a strategic research partnership in targeting misfolded proteins implicated in neurodegenerative diseases.
The collaboration covers a large drug discovery program targeting both tau and amyloïde-β (Aβ), two key proteins involved in Alzheimer’s disease. This therapeutic strategy aims to provide patients with a drug that slows the progression of pathology in the brain, thereby minimizing functional decline through a disease-modifying mechanism.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze